These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 31607486)

  • 1. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased total psoas muscle area after neoadjuvant therapy is a predictor of increased mortality in patients undergoing oesophageal cancer resection.
    Yassaie SS; Keane C; French SJH; Al-Herz FAJ; Young MK; Gordon AC
    ANZ J Surg; 2019 May; 89(5):515-519. PubMed ID: 30959566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantity and Quality of Skeletal Muscle as an Important Predictor of Clinical Outcomes in Patients with Esophageal Cancer Undergoing Esophagectomy after Neoadjuvant Chemotherapy.
    Ishida T; Makino T; Yamasaki M; Yamashita K; Tanaka K; Saito T; Yamamoto K; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Eguchi H; Doki Y
    Ann Surg Oncol; 2021 Nov; 28(12):7185-7195. PubMed ID: 33876359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.
    Järvinen T; Ilonen I; Kauppi J; Salo J; Räsänen J
    World J Surg Oncol; 2018 Feb; 16(1):27. PubMed ID: 29433514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of preoperative psoas muscle index as a measure of nutritional status in patients with esophageal cancer receiving neoadjuvant therapy.
    Nakayama T; Furuya S; Kawaguchi Y; Shoda K; Akaike H; Hosomura N; Amemiya H; Kawaida H; Sudoh M; Kono H; Ichikawa D
    Nutrition; 2021 Oct; 90():111232. PubMed ID: 33964490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.
    Ozawa Y; Nakano T; Taniyama Y; Sakurai T; Onodera Y; Kamiya K; Hikage M; Sato C; Takaya K; Konno T; Unno M; Kamei T
    Esophagus; 2019 Oct; 16(4):345-351. PubMed ID: 30980203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low psoas muscle index has a negative impact on survival after minimal invasive esophagectomy for cancer in European men.
    Mann C; Jezycki T; Berlth F; Hadzijusufovic E; Uzun E; Lang H; Kloeckner R; Grimminger PP
    Eur J Surg Oncol; 2024 Oct; 50(10):108533. PubMed ID: 39094525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on postoperative complications of changes in skeletal muscle mass during neoadjuvant chemotherapy for gastro-oesophageal cancer.
    den Boer RB; Jones KI; Ash S; van Boxel GI; Gillies RS; O'Donnell T; Ruurda JP; Sgromo B; Silva MA; Maynard ND
    BJS Open; 2020 Oct; 4(5):847-854. PubMed ID: 32841538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreases in the Psoas Muscle Index Correlate More Strongly with Survival than Other Prognostic Markers in Esophageal Cancer After Neoadjuvant Chemoradiotherapy Plus Esophagectomy.
    Kawakita Y; Motoyama S; Sato Y; Wakita A; Nagaki Y; Imai K; Minamiya Y
    World J Surg; 2020 May; 44(5):1559-1568. PubMed ID: 31907570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.
    Kamitani N; Migita K; Matsumoto S; Wakatsuki K; Kunishige T; Nakade H; Miyao S; Sho M
    Surg Today; 2019 Dec; 49(12):1022-1028. PubMed ID: 31309328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative Assessment of Muscle Mass Using Computerized Tomography Scans to Predict Outcomes Following Orthotopic Liver Transplantation.
    Esser H; Resch T; Pamminger M; Mutschlechner B; Troppmair J; Riedmann M; Gassner E; Maglione M; Margreiter C; Boesmueller C; Oberhuber R; Weissenbacher A; Cardini B; Finkenstedt A; Zoller H; Tilg H; Öfner D; Schneeberger S
    Transplantation; 2019 Dec; 103(12):2506-2514. PubMed ID: 30985737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer.
    Kita R; Miyata H; Sugimura K; Tanaka K; Makino T; Yamashita K; Yamasaki M; Motoori M; Shiraishi O; Kimura Y; Yasuda T; Yano M; Doki Y
    Clin Nutr; 2021 Jun; 40(6):4380-4385. PubMed ID: 33526287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of skeletal muscle wasting during neoadjuvant chemotherapy on postoperative anastomotic leakage in patients with esophageal cancer.
    Fujihata S; Ogawa R; Nakaya S; Hayakawa S; Okubo T; Sagawa H; Tanaka T; Takahashi H; Matsuo Y; Takiguchi S
    Esophagus; 2021 Apr; 18(2):258-266. PubMed ID: 32889673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-operative psoas muscle index, a surrogate for sarcopenia; as a predictor of post-esophagectomy complications.
    Yunrong T; Jin WW; Mahendran HA; Koon YB; Jahit S; Kamaruddin MA; Anuar N; Daud NAM
    Dis Esophagus; 2024 Apr; 37(4):. PubMed ID: 38163959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
    Ida S; Watanabe M; Karashima R; Imamura Y; Ishimoto T; Baba Y; Iwagami S; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Oct; 21(11):3675-9. PubMed ID: 24793436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal muscle wasting during neoadjuvant therapy as a prognosticator in patients with esophageal and esophagogastric junction cancer: A systematic review and meta-analysis.
    Wang P; Wang S; Li X; Lin G; Ma Y; Xiao R; Li H; Qiu M; Yang F
    Int J Surg; 2022 Jan; 97():106206. PubMed ID: 34990833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.